Mission To Complete Remission: Utilizing MRD Testing In Blood Cancer

Adriana Rossi, MD

Testing for minimal or measurable residual disease (MRD) in blood cancer has transformed the way we look at remission and treatment planning.

In this episode, we speak to Dr. Adriana Rossi of Mt. Sinai Hospital in New York about how MRD testing is being utilized for blood cancer patients. Join us as we explore minimal/measurable residual disease (MRD) testing for blood cancer and its role in guiding treatment decisions and predicting relapse and prognosis.   

CLICK HERE to participate in our episode survey.

Mentioned on this episode: 

Additional LLS Support Resources: 

Support for this episode provided by: Adaptive Biotechnologies


  1. Other than Myeloma, what about other blood cancers such a DLBC Lymphoma? Is this blood test the same for that subtype?

Leave a Comment

Your email address will not be published. Required fields are marked *